近日,先声药业拟分拆旗下抗肿瘤创新药平台先声再明赴港上市。在刚刚过去的2025年,先声药业研发管线喜讯不断:2款1类新药、1个首仿获批上市,3款1类新药提交NDA,5款1类新药首次获批临床等。截至目前,公司已有10款新药在国内获批上市,创新药收入逐年快速增长;此外,30余款新药在国内处于申请临床及以上阶段,6款1类新药上市可期。创新药“称王”!3个超10亿品种亮眼经过多年发展,先声药业已然成为一家...
Source Link近日,先声药业拟分拆旗下抗肿瘤创新药平台先声再明赴港上市。在刚刚过去的2025年,先声药业研发管线喜讯不断:2款1类新药、1个首仿获批上市,3款1类新药提交NDA,5款1类新药首次获批临床等。截至目前,公司已有10款新药在国内获批上市,创新药收入逐年快速增长;此外,30余款新药在国内处于申请临床及以上阶段,6款1类新药上市可期。创新药“称王”!3个超10亿品种亮眼经过多年发展,先声药业已然成为一家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.